Grifols, S.A. (NASDAQ:GRFS) Receives Average Recommendation of “Hold” from Analysts

Shares of Grifols, S.A. (NASDAQ:GRFSGet Rating) have received an average recommendation of “Hold” from the nine research firms that are covering the stock, MarketBeat reports. Two research analysts have rated the stock with a sell rating, three have given a hold rating and two have given a buy rating to the company. The average 1-year target price among brokers that have covered the stock in the last year is $16.20.

Several equities research analysts have recently weighed in on the stock. JPMorgan Chase & Co. decreased their price objective on shares of Grifols from €15.00 ($15.79) to €11.00 ($11.58) in a research report on Tuesday, January 4th. Zacks Investment Research cut shares of Grifols from a “hold” rating to a “sell” rating in a research report on Wednesday. Berenberg Bank decreased their price objective on shares of Grifols from €21.60 ($22.74) to €21.40 ($22.53) in a research report on Thursday, March 3rd. Morgan Stanley assumed coverage on shares of Grifols in a report on Friday, April 8th. They issued an “equal weight” rating for the company. Finally, StockNews.com assumed coverage on shares of Grifols in a report on Thursday, March 31st. They issued a “hold” rating for the company.

Large investors have recently bought and sold shares of the business. First Horizon Advisors Inc. lifted its stake in shares of Grifols by 8,984.6% in the third quarter. First Horizon Advisors Inc. now owns 2,362 shares of the biotechnology company’s stock valued at $107,000 after buying an additional 2,336 shares in the last quarter. JJJ Advisors Inc. lifted its stake in shares of Grifols by 106.2% in the fourth quarter. JJJ Advisors Inc. now owns 3,880 shares of the biotechnology company’s stock valued at $44,000 after buying an additional 1,998 shares in the last quarter. Parallel Advisors LLC lifted its stake in shares of Grifols by 367.8% in the fourth quarter. Parallel Advisors LLC now owns 4,360 shares of the biotechnology company’s stock valued at $49,000 after buying an additional 3,428 shares in the last quarter. Lindbrook Capital LLC lifted its stake in shares of Grifols by 657.5% in the fourth quarter. Lindbrook Capital LLC now owns 5,886 shares of the biotechnology company’s stock valued at $66,000 after buying an additional 5,109 shares in the last quarter. Finally, SG Americas Securities LLC bought a new position in shares of Grifols in the third quarter valued at $130,000. Institutional investors and hedge funds own 14.71% of the company’s stock.

GRFS opened at $11.15 on Wednesday. Grifols has a twelve month low of $10.10 and a twelve month high of $19.07. The company has a debt-to-equity ratio of 0.85, a quick ratio of 0.94 and a current ratio of 1.59. The business’s fifty day moving average price is $11.20. The firm has a market capitalization of $7.57 billion, a PE ratio of 9.78 and a beta of 0.43.

About Grifols (Get Rating)

Grifols, SA engages in the procurement, manufacture, preparation, and sale of therapeutic products, primarily hemoderivatives. The company operates through Bioscience, Hospital, Diagnostic, Bio Supplies, and Others divisions. The Bioscience division researches, develops, produces, and markets plasma-derived medicines and other innovative solutions to treat patients with chronic, rare, prevalent, and life-threatening diseases.

Featured Articles

Analyst Recommendations for Grifols (NASDAQ:GRFS)

Receive News & Ratings for Grifols Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Grifols and related companies with MarketBeat.com's FREE daily email newsletter.